BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lampertico P, Viganò M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, Soffredini R, Abrignani S, De Francesco R, Colombo M. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013;57:890-6. [PMID: 22473858 DOI: 10.1002/hep.25749] [Cited by in Crossref: 126] [Cited by in F6Publishing: 97] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Hajizadeh L, Samaei NM, Bazgir A, Agha Gholizadeh M, Khosravi A. Association of Interleukin-28B Polymorphisms (rs12979860 C/T, rs12980275 A/G, rs8099917 T/G) and Risk of Hepatocellular Carcinoma in an Iranian Population. Middle East J Dig Dis 2022;14:118-123. [DOI: 10.34172/mejdd.2022.264] [Reference Citation Analysis]
2 Alandağ C, Demirel U, Kargün K. Relationship Between Interleukin-28B Gene Polymorphism and Chronic Hepatitis B Infection. Medical Records 2022. [DOI: 10.37990/medr.1026615] [Reference Citation Analysis]
3 Ye J, Chen J. Interferon and Hepatitis B: Current and Future Perspectives. Front Immunol 2021;12:733364. [PMID: 34557195 DOI: 10.3389/fimmu.2021.733364] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
4 Ying SY, Hu YR, Gao GS, Lou KH, Huang Z. Interleukin-28B Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients With Chronic Hepatitis B: A Meta-Analysis. Front Med (Lausanne) 2021;8:691365. [PMID: 34307418 DOI: 10.3389/fmed.2021.691365] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Novotny LA, Evans JG, Su L, Guo H, Meissner EG. Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies. Viruses 2021;13:1090. [PMID: 34207487 DOI: 10.3390/v13061090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Boglione L, De Benedetto I, Lupia T, Cusato J, Cariti G, Di Perri G. Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study. Arch Virol 2021;166:1125-31. [PMID: 33580380 DOI: 10.1007/s00705-021-04992-5] [Reference Citation Analysis]
7 Lai M, Chen H, Chang M. Management of Chronic Hepatitis B Virus Infection in Children and Pregnant Women. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_16] [Reference Citation Analysis]
8 Papatheodoridi M, Papatheodoridis G. Chronic Hepatitis B Virus Infection: Interferon Therapy and Long-Term Outcomes. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yeh ML, Huang JF, Yu ML, Chuang WL. Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa. Expert Rev Gastroenterol Hepatol 2021;15:427-35. [PMID: 33338385 DOI: 10.1080/17474124.2021.1866985] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
10 Broquetas T, Garcia-Retortillo M, Micó M, Canillas L, Puigvehí M, Cañete N, Coll S, Viu A, Hernandez JJ, Bessa X, Carrión JA. Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients. World J Hepatol 2020; 12(11): 1076-1088 [PMID: 33312431 DOI: 10.4254/wjh.v12.i11.1076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
11 Fong IW. Major Advances in Hepatitis C Treatment but Not Hepatitis B. Current Trends and Concerns in Infectious Diseases 2020. [DOI: 10.1007/978-3-030-36966-8_5] [Reference Citation Analysis]
12 Lai MW, Chang MH. Updates in the management of hepatitis B in children. Expert Rev Gastroenterol Hepatol 2019;13:1065-76. [PMID: 31663387 DOI: 10.1080/17474124.2019.1686975] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Qin S, Wang J, Zhou C, Xu Y, Zhang Y, Wang X, Wang S. The influence of interleukin 28B polymorphisms on the risk of hepatocellular carcinoma among patients with HBV or HCV infection: An updated meta-analysis. Medicine (Baltimore). 2019;98:e17275. [PMID: 31568008 DOI: 10.1097/md.0000000000017275] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
14 Grzegorzewska AE. Genetic Polymorphisms within Interferon-λ Region and Interferon-λ3 in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses. CMC 2019;26:4832-51. [DOI: 10.2174/0929867325666180719121142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Zhang Z, Wang C, Liu Z, Zou G, Li J, Lu M. Host Genetic Determinants of Hepatitis B Virus Infection. Front Genet. 2019;10:696. [PMID: 31475028 DOI: 10.3389/fgene.2019.00696] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
16 Zhao Z, Qin Z, Zhou L, Xiang L, You J, Cao R, Wang H, Wang B, Li M. The impact of IFNL3 genotype on interferon treatment outcome in patients chronically infected with hepatitis B virus: A meta-analysis. Microb Pathog 2019;134:103598. [PMID: 31201901 DOI: 10.1016/j.micpath.2019.103598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Chmelova K, Frankova S, Jirsa M, Neroldova M, Sticova E, Merta D, Senkerikova R, Trunecka P, Spicak J, Sperl J. IL28B rs12979860 T allele protects against CMV disease in liver transplant recipients in the post-prophylaxis and late period. Transpl Infect Dis 2019;21:e13124. [PMID: 31165537 DOI: 10.1111/tid.13124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Thanapirom K, Suksawatamnuay S, Sukeepaisarnjaroen W, Treeprasertsuk S, Tanwandee T, Charatcharoenwitthaya P, Thongsawat S, Leerapun A, Piratvisuth T, Boonsirichan R, Bunchorntavakul C, Pattanasirigool C, Pornthisarn B, Tuntipanichteerakul S, Sripariwuth E, Jeamsripong W, Sanpajit T, Poovorawan Y, Komolmit P. Vitamin D-Binding protein Gene Polymorphism Predicts Pegylated Interferon-Related HBsAg Seroclearance in HBeAg-Negative Thai Chronic Hepatitis B Patients: A Multicentre Study. Asian Pac J Cancer Prev 2019;20:1257-64. [PMID: 31030503 DOI: 10.31557/APJCP.2019.20.4.1257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
19 Wang Y, Niu J, Deng G, Zhao Y. Host Genetic Characters of Acute Exacerbation of Chronic Hepatitis B (AECHB). Acute Exacerbation of Chronic Hepatitis B 2019. [DOI: 10.1007/978-94-024-1606-0_4] [Reference Citation Analysis]
20 O'Brien TR, Yang HI, Groover S, Jeng WJ. Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. Gastroenterology 2019;156:400-17. [PMID: 30287169 DOI: 10.1053/j.gastro.2018.09.052] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
21 Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019;118:7-38. [PMID: 30527436 DOI: 10.1016/j.jfma.2018.11.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
22 Wei L, Wedemeyer H, Liaw YF, Chan HL, Piratvisuth T, Marcellin P, Jia J, Tan D, Chow WC, Brunetto MR, Diago M, Gurel S, Morozov V, He H, Zhu Y, Wat C, Surujbally B, Thompson AJ. No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. PLoS One 2018;13:e0199198. [PMID: 30016335 DOI: 10.1371/journal.pone.0199198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
23 Wu Y, Zeng Y, Wu W, Lin J, Ou Q. Polymorphisms of CYP27B1 are associated with IFN efficacy in HBeAg-positive patients. J Clin Lab Anal 2018;32:e22367. [PMID: 29457277 DOI: 10.1002/jcla.22367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Asselah T, Marcellin P. Chronic HBV Infection: Interferon Therapy and Long-Term Outcomes. Hepatitis B Virus and Liver Disease 2018. [DOI: 10.1007/978-981-10-4843-2_10] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Lai M, Chen H, Chang M. Management of Chronic Hepatitis B Virus Infection in Children and Pregnant Women. Hepatitis B Virus and Liver Disease 2018. [DOI: 10.1007/978-981-10-4843-2_14] [Reference Citation Analysis]
26 Li Y, Wei T, Yan L, Yang Z, Huang Q, Shi Y, Wang L. Association of interleukin-28B polymorphisms with platelet count and liver function recovery after liver transplant. Medicine (Baltimore) 2017;96:e8219. [PMID: 29095252 DOI: 10.1097/MD.0000000000008219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
27 Grzegorzewska AE, Świderska MK, Mostowska A, Jagodziński PP. Circulating Interferon-λ3, Responsiveness to HBV Vaccination, and HBV/HCV Infections in Haemodialysis Patients. Biomed Res Int 2017;2017:3713025. [PMID: 29226133 DOI: 10.1155/2017/3713025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
28 Ghany MG, Gara N. Hepatitis B and D. Schiff's Diseases of the Liver 2017. [DOI: 10.1002/9781119251316.ch24] [Reference Citation Analysis]
29 Chen C, Zhu X, Xu W, Yang F, Zhang G, Wu L, Zheng Y, Gao Z, Xie C, Peng L. IFNA2 p.Ala120Thr impairs the inhibitory activity of Interferon-α2 against the hepatitis B virus through altering its binding to the receptor. Antiviral Res 2017;147:11-8. [PMID: 28958921 DOI: 10.1016/j.antiviral.2017.09.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
30 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-98. [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021] [Cited by in Crossref: 2573] [Cited by in F6Publishing: 2627] [Article Influence: 514.6] [Reference Citation Analysis]
31 Heidari Z, Moudi B, Mahmoudzadeh-Sagheb H, Moudi M. The association between interleukin-28B gene polymorphisms as a potential biomarker and the risk of chronic Periodontitis in an Iranian population. Head Face Med 2017;13:16. [PMID: 28655358 DOI: 10.1186/s13005-017-0148-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
32 Grzegorzewska AE, Świderska MK, Mostowska A, Warchoł W, Jagodziński PP. Polymorphisms of T helper cell cytokine-associated genes and survival of hemodialysis patients - a prospective study. BMC Nephrol 2017;18:165. [PMID: 28525983 DOI: 10.1186/s12882-017-0582-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
33 Li X, Li Y, Fang S, Su J, Jiang J, Liang B, Huang J, Zhou B, Zang N, Ho W, Li J, Li Y, Chen H, Ye L, Liang H. Downregulation of autophagy-related gene ATG5 and GABARAP expression by IFN-λ1 contributes to its anti-HCV activity in human hepatoma cells. Antiviral Res 2017;140:83-94. [PMID: 28131804 DOI: 10.1016/j.antiviral.2017.01.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
34 Boglione L, Cusato J, Cariti G, Di Perri G, D'avolio A. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon. Antiviral Research 2016;136:32-6. [DOI: 10.1016/j.antiviral.2016.10.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
35 Xie DY, Wang SM, Yang JM, Wang LH, Chen HY, Huai C, Shang J, Mao Q, Lei CL, Luo GH, Qian J, Lu DR. IFIT1 polymorphisms predict interferon-α treatment efficiency for hepatitis B virus infection. World J Gastroenterol 2016; 22(44): 9813-9821 [PMID: 27956805 DOI: 10.3748/wjg.v22.i44.9813] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
36 Domagalski K, Pawłowska M, Zaleśna A, Pilarczyk M, Rajewski P, Halota W, Tretyn A. Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus. World J Gastroenterol 2016; 22(41): 9186-9195 [PMID: 27895405 DOI: 10.3748/wjg.v22.i41.9186] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
37 Eslam M, George J. Targeting IFN-λ: therapeutic implications. Expert Opinion on Therapeutic Targets 2016;20:1425-32. [DOI: 10.1080/14728222.2016.1241242] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
38 Fuchs S, Kaiser-labusch P, Bank J, Ammann S, Kolb-kokocinski A, Edelbusch C, Omran H, Ehl S. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses. Eur J Immunol 2016;46:2639-49. [DOI: 10.1002/eji.201646519] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
39 Moudi B, Heidari Z, Mahmoudzadeh-sagheb H. Impact of host gene polymorphisms on susceptibility to chronic hepatitis B virus infection. Infection, Genetics and Evolution 2016;44:94-105. [DOI: 10.1016/j.meegid.2016.06.043] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
40 Krishnamoorthy TL, Mutimer D. Hepatitis B: encouraging the use of interferon. Curr Opin Infect Dis. 2015;28:557-562. [PMID: 26381998 DOI: 10.1097/QCO.0000000000000209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
41 Grzegorzewska AE, Świderska MK, Mostowska A, Warchoł W, Jagodziński PP. Antibodies to HBV surface antigen in relation to interferon-λ3 in hemodialysis patients. Vaccine 2016;34:4866-74. [PMID: 27595449 DOI: 10.1016/j.vaccine.2016.08.073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
42 Boglione L, Cariti G, Di Perri G, D'Avolio A. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B. J Med Virol. 2016;88:1953-1959. [PMID: 27017932 DOI: 10.1002/jmv.24534] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
43 Jiang DK, Wu X, Qian J, Ma XP, Yang J, Li Z, Wang R, Sun L, Liu F, Zhang P, Zhu X, Wu J, Chen K, Conran C, Zheng SL, Lu D, Yu L, Liu Y, Xu J. Genetic variation in STAT4 predicts response to interferon-α therapy for hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2016;63:1102-11. [PMID: 26704347 DOI: 10.1002/hep.28423] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
44 Isorce N, Testoni B, Locatelli M, Fresquet J, Rivoire M, Luangsay S, Zoulim F, Durantel D. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus. Antiviral Res. 2016;130:36-45. [PMID: 26971407 DOI: 10.1016/j.antiviral.2016.03.008] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 8.2] [Reference Citation Analysis]
45 Wong DJ, Locarnini SA, Thompson AJ. Hepatitis B Virus. Clinical Virology 2016. [DOI: 10.1128/9781555819439.ch32] [Reference Citation Analysis]
46 Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N, Hou J; Chronic Hepatitis B Study Consortium. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut 2016;65:313-20. [PMID: 25586058 DOI: 10.1136/gutjnl-2014-308546] [Cited by in Crossref: 87] [Cited by in F6Publishing: 80] [Article Influence: 14.5] [Reference Citation Analysis]
47 Lo VCK, Janssen HLA. IFN-Based Therapy and Management of Patients. Molecular and Translational Medicine 2016. [DOI: 10.1007/978-3-319-22330-8_15] [Reference Citation Analysis]
48 Andersson KL, Dienstag JL. Chronic Hepatitis B Viral Infection. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch95] [Reference Citation Analysis]
49 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1348] [Cited by in F6Publishing: 1457] [Article Influence: 192.6] [Reference Citation Analysis]
50 Lazear HM, Nice TJ, Diamond MS. Interferon-λ: Immune Functions at Barrier Surfaces and Beyond. Immunity 2015;43:15-28. [PMID: 26200010 DOI: 10.1016/j.immuni.2015.07.001] [Cited by in Crossref: 302] [Cited by in F6Publishing: 261] [Article Influence: 43.1] [Reference Citation Analysis]
51 Stättermayer AF, Ferenci P. Effect of IL28B genotype on hepatitis B and C virus infection. Curr Opin Virol 2015;14:50-5. [PMID: 26284971 DOI: 10.1016/j.coviro.2015.07.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
52 Huang DD, Bankowski MJ. Susceptibility Test Methods: Viruses. Manual ofClinical Microbiology 2015. [DOI: 10.1128/9781555817381.ch112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Enomoto M, Nishiguchi S, Tamori A, Kozuka R, Hayashi T, Kohmoto MT, Jomura H, Morikawa H, Murakami Y, Shiomi S. Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection. J Interferon Cytokine Res. 2015;35:613-620. [PMID: 25884105 DOI: 10.1089/jir.2014.0234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
54 Song K, Han C, Dash S, Balart LA, Wu T. MiR-122 in hepatitis B virus and hepatitis C virus dual infection. World J Hepatol 2015; 7(3): 498-506 [PMID: 25848473 DOI: 10.4254/wjh.v7.i3.498] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
55 Wang H, Wu H, Bao S, Xiang X, Zhao G, Liu K, Li F, Xu Y, An B, Zhou H, Lu J, Xie Q. Association of IPS1 polymorphisms with peginterferon efficacy in chronic hepatitis B with HBeAg-positive in the Chinese population. Infect Genet Evol 2015;31:161-8. [PMID: 25640825 DOI: 10.1016/j.meegid.2015.01.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
56 Griffiths SJ, Dunnigan CM, Russell CD, Haas JG. The Role of Interferon-λ Locus Polymorphisms in Hepatitis C and Other Infectious Diseases. J Innate Immun 2015;7:231-42. [PMID: 25634147 DOI: 10.1159/000369902] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
57 Dienstag JL, Delemos AS. Viral Hepatitis. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2015. [DOI: 10.1016/b978-1-4557-4801-3.00119-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
58 Wu X, Shi W, Wu J, Zhu X, Chen K, Zheng S, Li Z, Duan Z, Li H, Liu Y. A functional polymorphism in ADAR1 gene affects HBsAg seroclearance both spontaneously and interferon induced. Liver Int 2014;34:1560-5. [PMID: 24351124 DOI: 10.1111/liv.12444] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
59 Zeng T, Zhang W, Yu X, Liu X, Li M, Liu R, Chen L. Edge biomarkers for classification and prediction of phenotypes. Sci China Life Sci 2014;57:1103-14. [PMID: 25326072 DOI: 10.1007/s11427-014-4757-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
60 You CR, Lee SW, Jang JW, Yoon SK. Update on hepatitis B virus infection. World J Gastroenterol 2014; 20(37): 13293-13305 [PMID: 25309066 DOI: 10.3748/wjg.v20.i37.13293] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 54] [Article Influence: 6.8] [Reference Citation Analysis]
61 Jansen L, de Niet A, Stelma F, van Iperen EP, van Dort KA, Plat-Sinnige MJ, Takkenberg RB, Chin DJ, Zwinderman AH, Lopatin U, Kootstra NA, Reesink HW. HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels. J Hepatol 2014;61:730-7. [PMID: 24824278 DOI: 10.1016/j.jhep.2014.05.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
62 Takahashi T. Interleukin 28B genetic polymorphism and hepatitis B virus infection. World J Gastroenterol 2014; 20(34): 12026-12030 [PMID: 25232239 DOI: 10.3748/wjg.v20.i34.12026] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
63 Boettler T, Moradpour D, Thimme R, Zoulim F. Bridging basic science and clinical research: the EASL Monothematic Conference on Translational Research in Viral Hepatitis. J Hepatol 2014;61:696-705. [PMID: 24845610 DOI: 10.1016/j.jhep.2014.05.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
64 Vallet-Pichard A, Pol S. Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal. Therap Adv Gastroenterol. 2014;7:148-155. [PMID: 25057295 DOI: 10.1177/1756283x14524614] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
65 Zeng Z. Human genes involved in hepatitis B virus infection. World J Gastroenterol 2014; 20(24): 7696-7706 [PMID: 24976707 DOI: 10.3748/wjg.v20.i24.7696] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
66 Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053-2063. [PMID: 24954675 DOI: 10.1016/s0140-6736(14)60220-8] [Cited by in Crossref: 938] [Cited by in F6Publishing: 995] [Article Influence: 117.3] [Reference Citation Analysis]
67 Domagalski K, Pawłowska M, Zaleśna A, Tyczyno M, Skorupa-Kłaput M, Tretyn A, Halota W. The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection. Eur J Clin Microbiol Infect Dis 2014;33:2025-33. [PMID: 24924923 DOI: 10.1007/s10096-014-2172-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
68 Zimmer V, Lammert F. Role of genetics in diagnosis and therapy of acquired liver disease. Molecular Aspects of Medicine 2014;37:15-34. [DOI: 10.1016/j.mam.2013.10.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
69 Tunçbilek S. Relationship between cytokine gene polymorphisms and chronic hepatitis B virus infection. World J Gastroenterol 2014; 20(20): 6226-6235 [PMID: 24876743 DOI: 10.3748/wjg.v20.i20.6226] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
70 Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014; 20(20): 6262-6278 [PMID: 24876747 DOI: 10.3748/wjg.v20.i20.6262] [Cited by in CrossRef: 96] [Cited by in F6Publishing: 91] [Article Influence: 12.0] [Reference Citation Analysis]
71 Santantonio TA, Fasano M. Chronic hepatitis B: Advances in treatment. World J Hepatol 2014; 6(5): 284-292 [PMID: 24868322 DOI: 10.4254/wjh.v6.i5.284] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
72 Sunbul M. Hepatitis B virus genotypes: Global distribution and clinical importance. World J Gastroenterol 2014; 20(18): 5427-5434 [PMID: 24833873 DOI: 10.3748/wjg.v20.i18.5427] [Cited by in CrossRef: 241] [Cited by in F6Publishing: 234] [Article Influence: 30.1] [Reference Citation Analysis]
73 Tseng TC, Kao JH, Chen DS. Peginterferon α in the treatment of chronic hepatitis B. Expert Opin Biol Ther. 2014;14:995-1006. [PMID: 24738850 DOI: 10.1517/14712598.2014.907784] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
74 He D, Guo S, Zhu P, Tao S, Li M, Huang H, Wang J, Wang Y, Ding M. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients. Clin Microbiol Infect. 2014;20:O687-O693. [PMID: 25469947 DOI: 10.1111/1469-0691.12605] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
75 Boglione L, Cusato J, Cariti G, Di Perri G, D’Avolio A. The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon. J Infect. 2014;69:81-87. [PMID: 24631900 DOI: 10.1016/j.jinf.2014.02.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
76 Galmozzi E, Viganò M, Lampertico P. Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection? Aliment Pharmacol Ther 2014;39:569-78. [PMID: 24461198 DOI: 10.1111/apt.12631] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
77 Degasperi E, Viganò M, Aghemo A, Lampertico P, Colombo M. PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history. Expert Review of Anti-infective Therapy 2014;11:459-74. [DOI: 10.1586/eri.13.37] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
78 Yapali S, Talaat N, Lok AS. Management of hepatitis B: our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol 2014;12:16-26. [PMID: 23660419 DOI: 10.1016/j.cgh.2013.04.036] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 9.4] [Reference Citation Analysis]
79 Bravo D, Solano C, Giménez E, Remigia MJ, Corrales I, Amat P, Navarro D. Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. J Med Virol 2014;86:838-44. [PMID: 24374819 DOI: 10.1002/jmv.23865] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
80 Russell CD, Griffiths SJ, Haas J. Interferon lambda genetic polymorphisms and viral infection: the tip of the iceberg? DNA Cell Biol 2014;33:60-3. [PMID: 24329419 DOI: 10.1089/dna.2013.2261] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
81 Boglione L, Cusato J, Allegra S, Esposito I, Patti F, Cariti G, Di Perri G, D'Avolio A. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. Antiviral Res 2014;102:35-43. [PMID: 24316030 DOI: 10.1016/j.antiviral.2013.11.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
82 Zeng T, Sun SY, Wang Y, Zhu H, Chen L. Network biomarkers reveal dysfunctional gene regulations during disease progression. FEBS J 2013;280:5682-95. [PMID: 24107168 DOI: 10.1111/febs.12536] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 6.1] [Reference Citation Analysis]
83 Guo X, Yang G, Yuan J, Ruan P, Zhang M, Chen X, Zhou B. Genetic variation in interleukin 28B and response to antiviral therapy in patients with dual chronic infection with hepatitis B and C viruses. PLoS One. 2013;8:e77911. [PMID: 24147097 DOI: 10.1371/journal.pone.0077911] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
84 Martinot-peignoux M, Lapalus M, Laouénan C, Lada O, Netto-cardoso ACF, Boyer N, Ripault MP, Carvalho-filho R, Asselah T, Marcellin P. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. Journal of Clinical Virology 2013;58:401-7. [DOI: 10.1016/j.jcv.2013.08.010] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 5.8] [Reference Citation Analysis]
85 Charatcharoenwitthaya P, Piratvisuth T. Baseline and On-treatment Predictors of Chronic Hepatitis B Patients Receiving Pegylated Interferon Therapy in Asia. Curr Hepatitis Rep 2013;12:165-173. [DOI: 10.1007/s11901-013-0175-5] [Reference Citation Analysis]
86 Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013;58:923-31. [PMID: 23468172 DOI: 10.1002/hep.26376] [Cited by in Crossref: 71] [Cited by in F6Publishing: 47] [Article Influence: 7.9] [Reference Citation Analysis]
87 Seto W, Wong DK, Lai C, Yuen M. Reply to Liao et al. Clinical Infectious Diseases 2013;57:622-622. [DOI: 10.1093/cid/cit295] [Reference Citation Analysis]
88 Liao Y, Li Y, Cai B, Chen J, Wang L. Lack of Association Between Interleukin 28B Polymorphisms and Spontaneous Viral Clearance in Hepatitis B Virus Patients. Clinical Infectious Diseases 2013;57:620-2. [DOI: 10.1093/cid/cit293] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
89 Kim SU, Song KJ, Chang HY, Shin EC, Park JY, Kim do Y, Han KH, Chon CY, Ahn SH. Association between IL28B polymorphisms and spontaneous clearance of hepatitis B virus infection. PLoS One. 2013;8:e69166. [PMID: 23874902 DOI: 10.1371/journal.pone.0069166] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
90 Grammatikos G, Sarrazin C. IL28B und antivirale Therapie der Virushepatitis: Was bleibt? Gastroenterologe 2013;8:322-329. [DOI: 10.1007/s11377-013-0763-5] [Reference Citation Analysis]
91 Lampertico P, Galmozzi E, Colombo M. [PMID: 22707216 DOI: 10.1002/hep.25882] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
92 Arends P, Sonneveld MJ, Janssen HLA. Hepatitis B virus treatment: Which patients should be treated with interferon? Clin Liver Dis (Hoboken) 2013;2:18-20. [PMID: 30992814 DOI: 10.1002/cld.152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
93 Jilg N, Chung RT. One more piece in the interleukin 28B gene puzzle? The case of hepatitis B. Hepatology 2013;57:870-2. [PMID: 22911469 DOI: 10.1002/hep.26026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
94 Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, Huang HC, Lee KC, Chan CC, Lin MW. IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PLoS One. 2013;8:e58071. [PMID: 23469142 DOI: 10.1371/journal.pone.0058071] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
95 Seto WK, Wong DK, Kopaniszen M, Proitsi P, Sham PC, Hung IF, Fung J, Lai CL, Yuen MF. HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis. 2013;56:1695-1703. [PMID: 23449268 DOI: 10.1093/cid/cit121] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
96 Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45:164-171. [PMID: 23291588 DOI: 10.1038/ng.2521] [Cited by in Crossref: 701] [Cited by in F6Publishing: 735] [Article Influence: 77.9] [Reference Citation Analysis]
97 Dunford L, Carr MJ, Dean J, Nguyen LT, Ta Thi TH, Nguyen BT, Connell J, Coughlan S, Nguyen HT, Hall WW. A multicentre molecular analysis of hepatitis B and blood-borne virus coinfections in Viet Nam. PLoS One. 2012;7:e39027. [PMID: 22720022 DOI: 10.1371/journal.pone.0039027] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 4.4] [Reference Citation Analysis]
98 Takahashi T. Three cases of chronic hepatitis B in that interferon therapy was indicated. Kanzo 2012;53:853-861. [DOI: 10.2957/kanzo.53.853] [Reference Citation Analysis]